|
Active substance |
Larotrectinib |
|
Holder |
Bayer |
|
Status |
Closed |
|
Indication |
Treatment of adult and paediatric patients with locally advanced or metastatic solid tumors with a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion that cannot be treated satisfactorily with the available treatment options |
|
Public documents |
|
|
Last update |
19/04/2021 |
Vitrakvi
Last updated on